Temporary practice pause then resumption (TPPR) study design: An extension of the withdrawal study design to complementary and alternative medicine mind and body interventions (CAM-MABI)

Journal of Alternative and Complementary Medicine

Volumn 19, Issue 10, 2013, Pages 833-837

  Braun, M Miles ^a  

^a not available   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LISDEXAMFETAMINE; PLACEBO; QUETIAPINE;

ALTERNATIVE MEDICINE; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL PRACTICE; COMPLEMENTARY AND ALTERNATIVE MEDICINE MIND AND BODY INTERVENTION; DRUG SCREENING; GENERALIZED ANXIETY DISORDER; HEALTH CARE PERSONNEL; HUMAN; INTERVENTION STUDY; MATHEMATICAL PARAMETERS; PRIORITY JOURNAL; PROCESS DEVELOPMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); STUDY DESIGN; TEMPORARY PRACTICE PAUSE THEN RESUMPTION STUDY DESIGN;

EID: 84885762802     PISSN: 10755535     EISSN: 15577708     Source Type: Journal    
DOI: 10.1089/acm.2012.0669     Document Type: Article

References (17)

1. NIH/NCCAM Third Strategic Plan 2011-15. Online document at: Http://nccam.nih.gov/about/plans/2011/objective1.htm Accessed August 2, 2012.
2. NIH/NCCAM Meditation for Health Purposes Workshop: Executive Summary. Online document at: Http://nccam .nih.gov/news/events/meditation08/summary.htm Accessed August 2, 2012.
3. US Food and Drug Administration. 2001. Guidance for Industry: E10. Choice of Control Group and Related Issues in Clinical Trials. Online document at: Www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM073139.pdf Accessed May 8, 2013.
4. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use: Choice of Control Group and Related Issues in Clinical Trials. E10. 2000. Online document at: Www.ich.org/ fileadmin/Public-Web-Site/ICH-Products/Guidelines/Effi cacy/E10/Step4/E10- Guideline.pdf Accessed August 2, 2012.
5. Brefczinski-Lewis JA, Lutz A, Schaefer HS, et al. Neural correlates of attention expertise in long-term meditation practitioners. PNAS 2007;104:11483-11488.
6. Vyvanse FDA approval letter. 2012. Online document at: Www.accessdata.fda.gov/drugsatfda-docs/appletter/2012/ 021977s022ltr.pdf Accessed July 2, 2012.
7. Astra Zenica. 2006. Safety and efficacy maintenance study of quetiapine SR to treat GAD patients. (PLATINUM). Online document at: Http://clinicaltrials. gov/ct2/show/NCT00314210 Accessed May 8, 2013.
8. Uretsky BF, Young JB, Shahidi FE, et al. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: Results of the PROVED trial. J Am Coll Cardiol 1993;22:955-962.
9. Janssen Research & Development, LLC. 2010. A study of the safety and efficacy of CNTO 148 (golimumab) in children with juvenile idiopathic arthritis ( JIA) and multiple joint involvement who have poor response to methotrexate (GO KIDS). Online document at: Http://clinicaltrials.gov/ct2/ show/NCT01230827term = JIA&rank = 16 Accessed on August 2, 2012.
10. Acologix, Inc. 2008. A randomized-withdrawal phase 3 study evaluating the safety and efficacy of oral nalfurafine HCl (AC- 820) in subjects on hemodialysis with uremic pruritus (renal itch) (AC120-8231). Online document at: Http://clinicaltrials .gov/ct2/show/NCT00793156 Accessed August 2, 2012.
11. Hewitt DJ, Ho TW, Galer B, et al. Impact of responder definition on the enriched enrollment randomized withdrawal trial design for establishing proof of concept in neuropathic pain. Pain 2011;152:514-521.
12. Spitzer WO. Importance of valid measurements of benefit and risk. Med Toxicol 1986;1(SUPPL. 1):74-78.
13. U.S. Food and Drug Administration. 2005. Guidance for industry: Good pharmacovigilance practices and pharmacoepidemiologic assessment. Online document at: Http://www .fda.gov/downloads/regulatoryinformation/guidances/ucm 126834.pdf Accessed August 2, 2012.
14. Davidson RJ. Empirical explorations of mindfulness: Conceptual and methodological conundrums. Emotion 2010; 10:8-11.
15. Vyvanse patient package insert. 2012. Online document at: Http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/ 021977s022lbl.pdf Accessed August 2, 2012.
16. Wayne PM, Kaptchuk TJ. Challenges inherent to tai chi research: Part I-tai chi as a complex multicomponent intervention. J Altern Complement Med 2008;14:95-102.
17. NIH/NCCAM. Examples of CAM mind and body interventions. Online document at: Http://nccam.nih.gov/about/ plans/2011/objective1.htm Accessed August 2, 2012.